CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo
Executive Summary
Novartis exec discusses details around its agreements with CMS for outcomes based payments and indication-based pricing for Kymriah.
You may also be interested in...
CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah
'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.
CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.
Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.